Journal of Hepatology
Volume 49, Issue 3 , Pages 316-322 , September 2008

Cerebral immune activation in chronic hepatitis C infection: A magnetic resonance spectroscopy study

  • Daniel M. Forton

      Affiliations

    • Hepatology Section, Division of Medicine, Imperial College London, St. Mary’s Hospital, London, United Kingdom
    • Robert Steiner Magnetic Resonance Unit, MRC Clinical Sciences Centre, Imperial College London, Hammersmith Hospital, London, United Kingdom
    • Corresponding Author InformationCorresponding author. Present address: Department of Gastroenterology and Hepatology, St. George’s Hospital, University of London, Blackshaw Road, London SW17 0QT, United Kingdom. Tel.: +44 208 725 3032; fax: +44 208 725 3520.
    • ,
  • Gavin Hamilton

      Affiliations

    • Department of Radiology, University of California San Diego, San Diego, USA
    • ,
  • Joanna M. Allsop

      Affiliations

    • Robert Steiner Magnetic Resonance Unit, MRC Clinical Sciences Centre, Imperial College London, Hammersmith Hospital, London, United Kingdom
    • ,
  • Vijay P. Grover

      Affiliations

    • Hepatology Section, Division of Medicine, Imperial College London, St. Mary’s Hospital, London, United Kingdom
    • Robert Steiner Magnetic Resonance Unit, MRC Clinical Sciences Centre, Imperial College London, Hammersmith Hospital, London, United Kingdom
    • ,
  • Keith Wesnes

      Affiliations

    • Cognitive Drug Research Limited, Goring-on-Thames, United Kingdom
    • ,
  • Catherine O’Sullivan

      Affiliations

    • Robert Steiner Magnetic Resonance Unit, MRC Clinical Sciences Centre, Imperial College London, Hammersmith Hospital, London, United Kingdom
    • ,
  • Howard C. Thomas

      Affiliations

    • Hepatology Section, Division of Medicine, Imperial College London, St. Mary’s Hospital, London, United Kingdom
    • ,
  • Simon D. Taylor-Robinson

      Affiliations

    • Hepatology Section, Division of Medicine, Imperial College London, St. Mary’s Hospital, London, United Kingdom
    • Robert Steiner Magnetic Resonance Unit, MRC Clinical Sciences Centre, Imperial College London, Hammersmith Hospital, London, United Kingdom

Received 10 February 2008 ,Accepted 6 March 2008.

References 

  1. Davis GL, Balart LA, Schiff ER, Lindsay K, Bodenheimer HC, Perrillo RP, et al. Assessing health-related quality of life in chronic hepatitis C using the sickness impact profile. Clin Ther. 1994;16:334–343
  2. Lee DH, Jamal H, Regenstein FG, Perrillo RP. Morbidity of chronic hepatitis C as seen in a tertiary care medical center. Dig Dis Sci. 1997;42:186–191
  3. Foster GR, Goldin RD, Thomas HC. Chronic hepatitis C virus infection causes a significant reduction in quality of life in the absence of cirrhosis. Hepatology. 1998;27:209–212
  4. Goh J, Coughlan B, Quinn J, O’Keane JC, Crowe J. Fatigue does not correlate with the degree of hepatitis or the presence of autoimmune disorders in chronic hepatitis C infection. Eur J Gastroenterol Hepatol. 1999;11:833–838
  5. Jamal MM, Soni A, Quinn PG, Wheeler DE, Arora S, Johnston DE. Clinical features of hepatitis C-infected patients with persistently normal alanine transaminase levels in the Southwestern United States. Hepatology. 1999;30:1307–1311
  6. Ware JEJ, Bayliss MS, Mannocchia M, Davis GL. Health-related quality of life in chronic hepatitis C: impact of disease and treatment response. Hepatology. 1999;30:550–555
  7. Bonkovsky HL, Woolley JM. Reduction of health-related quality of life in chronic hepatitis C and improvement with interferon therapy. Hepatology. 1999;29:264–270
  8. Kenny-Walsh E. Clinical outcomes after hepatitis C infection from contaminated anti-D immune globulin. N Engl J Med. 1999;340:1228–1233
  9. Barkhuizen A, Rosen HR, Wolf S, Flora K, Benner K, Bennett RM. Musculoskeletal pain and fatigue are associated with chronic hepatitis C: a report of 239 hepatology clinic patients. Am J Gastroenterol. 1999;94:1355–1360
  10. Clifford DB, Evans SR, Yang Y, Gulick RM. The neuropsychological and neurological impact of hepatitis C virus co-infection in HIV-infected subjects. AIDS. 2005;19:S64–S71
  11. Forton DM, Thomas HC, Murphy CA, Allsop JM, Foster GR, Main J, et al. Hepatitis C and cognitive impairment in a cohort of patients with mild liver disease. Hepatology. 2002;35:433–439
  12. Hilsabeck RC, Perry W, Hassanein TI. Neuropsychological impairment in patients with chronic hepatitis C. Hepatology. 2002;35:440–446
  13. Hilsabeck RC, Hassanein TI, Carlson MD, Ziegler EA, Perry W. Cognitive functioning and psychiatric symptomatology in patients with chronic hepatitis C. J Int Neuropsychol Soc. 2003;9:847–854
  14. Cordoba J, Flavia M, Jacas C, Sauleda S, Esteban JI, Vargas V, et al. Quality of life and cognitive function in hepatitis C at different stages of liver disease. J Hepatol. 2003;39:231–238
  15. Weissenborn K, Krause J, Bokemeyer M, Hecker H, Schuler A, Ennen JC, et al. Hepatitis C virus infection affects the brain-evidence from psychometric studies and magnetic resonance spectroscopy. J Hepatol. 2004;41:845–851
  16. McAndrews MP, Farcnik K, Carlen P, Damyanovich A, Mrkonjik M, Jones S, et al. Prevalence and significance of neurocognitive dysfunction in hepatitis C in the absence of correlated risk factors. Hepatology. 2005;41:801–808
  17. Rodger AJ, Jolley D, Thompson SC, Lanigan A, Crofts N. The impact of diagnosis of hepatitis C virus on quality of life. Hepatology. 1999;30:1299–1301
  18. Dwight MM, Kowdley KV, Russo JE, Ciechanowski PS, Larson AM, Katon WJ. Depression, fatigue, and functional disability in patients with chronic hepatitis C. J Psychosom Res. 2000;49:311–317
  19. Hauser W, Zimmer C, Schiedermaier P, Grandt D. Biopsychosocial predictors of health-related quality of life in patients with chronic hepatitis C. Psychosom Med. 2004;66:954–958
  20. Cordoba J, Reyes J, Esteban JI, Hernandez JM. Labeling may be an important cause of reduced quality of life in chronic hepatitis C. Am J Gastroenterol. 2003;98:226–227
  21. Hilsabeck RC, Hassanein TI, Perry W. Biopsychosocial predictors of fatigue in chronic hepatitis C. J Psychosom Res. 2005;58:173–178
  22. Radkowski M, Wilkinson J, Nowicki M, Adair D, Vargas H, Ingui C, et al. Search for hepatitis C virus negative-strand RNA sequences and analysis of viral sequences in the central nervous system: evidence of replication. J Virol. 2002;76:600–608
  23. Vargas HE, Laskus T, Radkowski M, Wilkinson J, Balan V, Douglas DD, et al. Detection of hepatitis C virus sequences in brain tissue obtained in recurrent hepatitis C after liver transplantation. Liver Transpl. 2002;8:1014–1019
  24. Forton DM, Karayiannis P, Mahmud N, Taylor-Robinson SD, Thomas HC. Identification of unique hepatitis C virus quasispecies in the central nervous system and comparative analysis of internal translational efficiency of brain, liver, and serum variants. J Virol. 2004;78:5170–5183
  25. Forton DM, Allsop JM, Main J, Foster GR, Thomas HC, Taylor-Robinson SD. Evidence for a cerebral effect of the hepatitis C virus. Lancet. 2001;358:38–39
  26. Barker PB, Lee RR, McArthur JC. AIDS dementia complex: evaluation with proton MR spectroscopic imaging. Radiology. 1995;195:58–64
  27. Meyerhoff DJ, Bloomer C, Cardenas V, Norman D, Weiner MW, Fein G. Elevated subcortical choline metabolites in cognitively and clinically asymptomatic HIV+ patients. Neurology. 1999;52:995–1003
  28. Laubenberger J, Haussinger D, Bayer S, Thielemann S, Schneider B, Mundinger A, et al. HIV-related metabolic abnormalities in the brain: depiction with proton MR spectroscopy with short echo times. Radiology. 1996;199:805–810
  29. Lopez-Villegas D, Lenkinski RE, Frank I. Biochemical changes in the frontal lobe of HIV-infected individuals detected by magnetic resonance spectroscopy. Proc Natl Acad Sci USA. 1997;94:9854–9859
  30. Salvan AM, Vion-Dury J, Confort-Gouny S, Nicoli F, Lamoureux S, Cozzone PJ. Cerebral metabolic alterations in human immunodeficiency virus-related encephalopathy detected by proton magnetic resonance spectroscopy. Comparison between sequences using short and long echo times. Invest Radiol. 1997;32:485–495
  31. Haussinger D, Laubenberger J, vom Dahl S, Ernst T, Bayer S, Langer M, et al. Proton magnetic resonance spectroscopy studies on human brain myo-inositol in hypo-osmolarity and hepatic encephalopathy. Gastroenterology. 1994;107:1475–1480
  32. Bitsch A, Bruhn H, Vougioukas V, Stringaris A, Lassmann H, Frahm J, et al. Inflammatory CNS demyelination: histopathologic correlation with in vivo quantitative proton MR spectroscopy. AJNR Am J Neuroradiol. 1999;20:1619–1627
  33. Avison MJ, Nath A, Berger JR. Understanding pathogenesis and treatment of HIV dementia: a role for magnetic resonance?. Trends Neurosci. 2002;25:468–473
  34. Tracey I, Carr CA, Guimaraes AR, Worth JL, Navia BA, Gonzalez RG. Brain choline-containing compounds are elevated in HIV-positive patients before the onset of AIDS dementia complex: a proton magnetic resonance spectroscopic study. Neurology. 1996;46:783–788
  35. Chang L, Ernst T, Leonido-Yee M, Walot I, Singer E. Cerebral metabolite abnormalities correlate with clinical severity of HIV-1 cognitive motor complex. Neurology. 1999;52:100–108
  36. Chang L, Ernst T, Witt MD, Ames N, Gaiefsky M, Miller E. Relationships among brain metabolites, cognitive function, and viral loads in antiretroviral-naive HIV patients. Neuroimage. 2002;17:1638–1648
  37. Goodman ZD, Ishak KG. Histopathology of hepatitis C virus infection. Semin Liver Dis. 1995;15:70–81
  38. Van den Boogaart A, Van Hecke P, Van Huffel S, Graveron-Demilly D, Van Ormondt D, De Beer R. MRUI: a graphical user interface for accurate routine MRS data analysis. In: Proceedings of the ESMRMB 13th Annual Meeting, Prague; 1996.
  39. McKeith I, Del Ser T, Spano F, Wesnes K, Anand R, Cicin-Sain A, et al. Efficacy of rivastigmine in dementia with Lewy bodies: results of a randomised placebo-controlled international study. Lancet. 2000;356:2031–2036
  40. Wesnes K, Ward T, McGinty A, Petrini O. The memory enhancing effects of a Ginkgo biloba/Panax ginseng combination in middle-age volunteers. Psychopharmacology. 2000;152:353–361
  41. Vanhamme L, van den Boogaart A, Van Huffel S. Improved method for accurate and efficient quantification of MRS data with use of prior knowledge. J Magn Reson. 1997;129:35–43
  42. Hamilton G, Patel N, Forton DM, Hajnal JV, Taylor-Robinson SD. Prior knowledge for time domain quantification of in vivo brain or liver 31P MR spectra. NMR Biomed. 2003;16:168–176
  43. in’t Zandt H, van Der Graaf M, Heerschap A. Common processing of in vivo MR spectra. NMR Biomed. 2001;14:224–232
  44. Kreis R, Ernst T, Ross BD. Absolute quantitation of water and metabolites in the human brain. II. Metabolite concentrations. J Magn Reson, B. 1993;102:9–19
  45. Chang L, Ernst T, Grob CS, Poland RE. Cerebral (1)H MRS alterations in recreational 3, 4- methylenedioxymethamphetamine (MDMA, “ecstasy”) users. J Magn Reson Imaging. 1999;10:521–526
  46. Chang L, Ernst T, Speck O, Grob CS. Additive effects of HIV and chronic methamphetamine use on brain metabolite abnormalities. Am J Psychiatry. 2005;162:361–369
  47. Taylor MJ, Letendre SL, Schweinsburg BC, Alhassoon OM, Brown GG, Gongvatana A, et al. Hepatitis C virus infection is associated with reduced white matter N-acetylaspartate in abstinent methamphetamine users. J Int Neuropsychol Soc. 2004;10:110–113
  48. Kraus MR, Schafer A, Mann S, Reimer P, Scheurlen M. Neurocognitive changes in patients with hepatitis C receiving interferon alfa-2b and ribavirin. Clin Pharmacol Ther. 2005;77:90–100
  49. Raison CL, Demetrashvili M, Capuron L, Miller AH. Neuropsychiatric adverse effects of interferon-[alpha]: recognition and management. CNS Drugs. 2005;19:105–123
  50. Capuron L, Ravaud A, Dantzer R. Timing and specificity of the cognitive changes induced by interleukin-2 and interferon-{alpha} treatments in cancer patients. Psychosom Med. 2001;63:376–386
  51. Aubert A, Vega C, Dantzer R, Goodall G. Pyrogens specifically disrupt the acquisition of a task involving cognitive processing in the rat. Brain Behav Immun. 1995;9:129–148
  52. Kent S, Bret-Dibat JL, Kelley KW, Dantzer R. Mechanisms of sickness-induced decreases in food-motivated behavior. Neurosci Biobehav Rev. 1996;20:171–175
  53. Dantzer R. Cytokine-induced sickness behaviour: a neuroimmune response to activation of innate immunity. Eur J Pharmacol. 2004;500:399–411
  54. Banks WA, Farr SA, Morley JE. Entry of blood-borne cytokines into the central nervous system: effects on cognitive processes. Neuroimmunomodulation. 2002;10:319–327
  55. Bluthe RM, Michaud B, Kelley KW, Dantzer R. Vagotomy blocks behavioural effects of interleukin-1 injected via the intraperitoneal route but not via other systemic routes. Neuroreport. 1996;7:2823–2827
  56. Huang YS, Hwang SJ, Chan CY, Wu JC, Chao Y, Chang FY, et al. Serum levels of cytokines in hepatitis C-related liver disease: a longitudinal study. Chung Hua I Hsueh Tsa Chih (Taipei). 1999;62:327–333
  57. Cacciarelli TV, Martinez OM, Gish RG, Villanueva JC, Krams SM. Immunoregulatory cytokines in chronic hepatitis C virus infection: pre- and posttreatment with interferon alfa. Hepatology. 1996;24:6–9
  58. Nguyen KT, Deak T, Owens SM, Kohno T, Fleshner M, Watkins LR, et al. Exposure to acute stress induces brain interleukin-1beta protein in the rat. J Neurosci. 1998;18:2239–2246
  59. Aloisi F. Immune function of microglia. Glia. 2001;36:165–179
  60. Hayley S, Merali Z, Anisman H. Stress and cytokine-elicited neuroendocrine and neurotransmitter sensitization: implications for depressive illness. Stress. 2003;6:19–32
  61. Morikawa O, Sakai N, Obara H, Saito N. Effects of interferon-[alpha], interferon-[gamma] and cAMP on the transcriptional regulation of the serotonin transporter. Eur J Pharmacol. 1998;349:317–324
  62. Kamata M, Higuchi H, Yoshimoto M, Yoshida K, Shimizu T. Effect of single intracerebroventricular injection of [alpha]-interferon on monoamine concentrations in the rat brain. Eur Neuropsychopharmacol. 2000;10:129–132
  63. Musselman DL, Lawson DH, Gumnick JF, Manatunga AK, Penna S, Goodkin RS, et al. Paroxetine for the prevention of depression induced by high-dose interferon alfa. N Engl J Med. 2001;344:961–966
  64. Weissenborn K, Ennen JC, Bokemeyer M, Ahl B, Wurster U, Tillmann HL, et al. Monoaminergic neurotransmission is altered in hepatitis C virus infected patients with chronic fatigue and cognitive impairment. Gut. 2006;56:624–630

☆ The authors declare that they do not have anything to disclose regarding funding from industries or conflict of interest with respect to this manuscript.

PII: S0168-8278(08)00228-6

doi: 10.1016/j.jhep.2008.03.022

Journal of Hepatology
Volume 49, Issue 3 , Pages 316-322 , September 2008

Article Tools

* Image Usage & Resolution